Added to YB: 2025-02-19
Pitch date: 2025-02-18
DTIL [bullish]
Precision BioSciences, Inc.
-6.64%
current return
Author Info
Value Never Sleeps shares value investment ideas in micro cap stocks. Sign up for the newsletter.
Company Info
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.
Market Cap
$141.5M
Pitch Price
$5.34
Price Target
28.00 (+461%)
Dividend
N/A
EV/EBITDA
-1.46
P/E
-0.71
EV/Sales
180.23
Sector
Biotechnology
Category
growth
Precision BioSciences (DTIL): A Deeply Undervalued Biotech With Short-Squeeze Potential
DTIL: Gene therapy co w/ ARCUS platform. Cash $110M, mkt cap $40.4M. Positive trials for ECUR-506 & azer-cel. Potential $2B+ milestones, royalties from partnerships. Near-term catalysts: earnings 3/12, clinical updates. Risks: dilution, trial failures. Target $9.20-$28. Current price ~$0.35.
Read full article (6 min)